Boryung Pharmaceutical Acquires Domestic Rights for US Lilly's Schizophrenia Treatment for 37.6 Billion KRW

[Asia Economy Reporter Ji Yeon-jin] Boryung Pharmaceutical announced on the 21st that it has acquired the domestic distribution rights for the schizophrenia treatment drug Zyprexa from the US pharmaceutical company Lilly for $32 million (KRW 37.6 billion). The contract period starts from today with no expiration.

The company explained that Zyprexa, launched in 1996, is the most prescribed schizophrenia treatment drug worldwide, and it continues to hold the number one prescription amount domestically with over 50% market share in the olanzapine market (KRW 14 billion in sales as of last year).